Invited Article: Comparative effectiveness research, evidence-based medicine, and the AAN

Neurology

Volumn 75, Issue 6, 2010, Pages 562-567

  French, Jacqueline A ^a   England, John D ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICONVULSIVE AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CLOPIDOGREL; ENTACAPONE; ETIRACETAM; HEPARIN; IMMUNOGLOBULIN; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE; VALPROIC ACID; WARFARIN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ENDARTERECTOMY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; DECISION MAKING; EPILEPSY; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; FUNDING; GENERALIZED EPILEPSY; GUILLAIN BARRE SYNDROME; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; LAW; MEDICAL RESEARCH; MEDICAL SPECIALIST; NEUROLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARTIAL EP; PLASMAPHERESIS; POLITICS; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; MEDICAL SOCIETY; PROCEDURES; STANDARDS; TRENDS; UNITED STATES;

COMPARATIVE EFFECTIVENESS RESEARCH; EVIDENCE-BASED MEDICINE; HUMANS; NEUROLOGY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77955445091     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181ec7f56     Document Type: Article

References (29)

1. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med 2009;151:203-205.
2. Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources-the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report, part I. Value Health 2009;12:1044-1052.
3. Winslow R. Study questions evidence behind heart therapies. Wall Street Journal. February 25, 2009.
4. Reinhardt UE. "Cost-effectiveness analysis" and U.S. health care. New York Times March 13, 2009.
5. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology 2008;71:1634-1638.
6. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-995.
7. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
8. Bath PM, Iddenden R, Bath FJ. Low-molecular-weight hepa-rins and heparinoids in acute ischemic stroke: a meta-analysis of randomized controlled trials. Stroke 2000;31:1770-1778.
9. Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 2002;33:1934-1942.
10. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-1249.
11. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracra-nial arterial stenosis. N Engl J Med 2005;352:1305-1316.
12. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-1671.
13. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent isch-emic stroke. N Engl J Med 2001;345:1444-1451.
14. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491-1502.
15. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of end-arterectomy for symptomatic carotid stenosis. Lancet 2003;361:107-116.
16. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251.
17. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004:CD000187.
18. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992;326:1123-1129.
19. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome. Neurology 1996;46:100-103.
20. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997;349:225-230.
21. Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 2009;360:1925-1927.
22. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology 2008;71:1639-1643.
23. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-1026. (Pubitemid 46436125)
24. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapen-tin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1000-1015.
25. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2009;73:133-141.
26. Panayiotopoulos CP. Evidence-based epileptology, randomized controlled trials, and SANAD: a critical clinical view. Epilepsia 2007;48:1268-1274.
27. Ferrie CD, Grunewald RA, Livingston JH, Panayiotopou-los CP. Treatment of newly diagnosed epilepsies: the shortcomings of SANAD. Dev Med Child Neurol 2008; 50:247.
28. French JA. First-choice drug for newly diagnosed epilepsy. Lancet 2007;369:970-971.
29. Johnston SC, Hauser SL. Comparative effectiveness research in the neurosciences. Ann Neurol 2009;65:A6-A8.